These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34364034)

  • 1. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
    Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM
    Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
    Eisele P; Szabo K; Ebert A; Platten M; Gass A
    J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain volume increase after discontinuing natalizumab therapy: Evidence for reversible pseudoatrophy.
    Nakamura K; Elliott C; Lee H; Narayanan S; Arnold DL
    Mult Scler Relat Disord; 2024 Jan; 81():105123. PubMed ID: 37976981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset.
    Storelli L; Pagani E; Pantano P; Piervincenzi C; Tedeschi G; Gallo A; De Stefano N; Battaglini M; Rocca MA; Filippi M;
    J Magn Reson Imaging; 2023 Oct; 58(4):1221-1231. PubMed ID: 36661195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
    PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.
    Gentile G; Mattiesing RM; Brouwer I; van Schijndel RA; Uitdehaag BMJ; Twisk JWR; Kappos L; Freedman MS; Comi G; Jack D; Barkhof F; De Stefano N; Vrenken H; Battaglini M
    Neuroimage Clin; 2023; 38():103397. PubMed ID: 37086648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX.
    Jasperse B; Valsasina P; Neacsu V; Knol DL; De Stefano N; Enzinger C; Smith SM; Ropele S; Korteweg T; Giorgio A; Anderson V; Polman CH; Filippi M; Miller DH; Rovaris M; Barkhof F; Vrenken H;
    J Magn Reson Imaging; 2007 Oct; 26(4):881-5. PubMed ID: 17896359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate.
    Honce JM; Nair KV; Hoyt BD; Seale RA; Sillau S; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Alvarez E
    Front Neurol; 2020; 11():1045. PubMed ID: 33071934
    [No Abstract]   [Full Text] [Related]  

  • 12. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.
    De Stefano N; Stromillo ML; Giorgio A; Bartolozzi ML; Battaglini M; Baldini M; Portaccio E; Amato MP; Sormani MP
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):93-9. PubMed ID: 25904813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
    Sastre-Garriga J; Tur C; Pareto D; Vidal-Jordana A; Auger C; Río J; Huerga E; Tintoré M; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):749-56. PubMed ID: 25392330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validation study of manual atrophy measures in patients with Multiple Sclerosis.
    Cappelle S; Pareto D; Tintoré M; Vidal-Jordana A; Alyafeai R; Alberich M; Sastre-Garriga J; Auger C; Montalban X; Rovira À
    Neuroradiology; 2020 Aug; 62(8):955-964. PubMed ID: 32246177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Pichler A; Khalil M; Langkammer C; Pinter D; Bachmaier G; Ropele S; Fuchs S; Enzinger C; Fazekas F
    Mult Scler; 2016 Mar; 22(3):340-6. PubMed ID: 26163072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.
    Uher T; Krasensky J; Vaneckova M; Sobisek L; Seidl Z; Havrdova E; Bergsland N; Dwyer MG; Horakova D; Zivadinov R
    J Neuroimaging; 2017 Nov; 27(6):620-629. PubMed ID: 28464417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis.
    Healy BC; Buckle GJ; Ali EN; Egorova S; Khalid F; Tauhid S; Glanz BI; Chitnis T; Guttmann CRG; Weiner HL; Bakshi R
    J Neuroimaging; 2017 Sep; 27(5):481-485. PubMed ID: 28261936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aging and Brain Atrophy in Multiple Sclerosis.
    Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Paunkoski I; Ramasamy DP; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    J Neuroimaging; 2019 Jul; 29(4):527-535. PubMed ID: 31074192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.